Christopher Famulare

4.0k total citations · 1 hit paper
32 papers, 1.3k citations indexed

About

Christopher Famulare is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Christopher Famulare has authored 32 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 16 papers in Molecular Biology and 11 papers in Genetics. Recurrent topics in Christopher Famulare's work include Acute Myeloid Leukemia Research (28 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Histone Deacetylase Inhibitors Research (8 papers). Christopher Famulare is often cited by papers focused on Acute Myeloid Leukemia Research (28 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Histone Deacetylase Inhibitors Research (8 papers). Christopher Famulare collaborates with scholars based in United States, Israel and Canada. Christopher Famulare's co-authors include Jessica Schulman, Minal Patel, Ari Melnick, Christopher E. Mason, Sara Zaccara, Diu Nguyen, Michael G. Kharas, Matthew MacKay, Samie R. Jaffrey and Brian F. Pickering and has published in prestigious journals such as Nature Medicine, Blood and Cancer.

In The Last Decade

Christopher Famulare

30 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells

2017 932 citations Ly Vu, Brian F. Pickering et al. Nature Medicine profile →

Peers

Christopher Famulare

HEMAT

EEE

GENET

Kai Hu China

Tara Gregory United States

Naoya Tatsumi Japan

Claudia Tschulik Germany

Naomi Porret Switzerland

Candida Vitale Italy

Haiwen Huang China

Andrea N. Marcogliese United States

Sascha Haubner Germany

William B. Donnellan United States

Kai Hu China

Christopher Famulare

220 ×0.2

106 ×0.2

106 ×0.3

HEMAT

16 ×0.1

EEE

45 ×0.3

GENET

Citations per year, relative to Christopher Famulare Christopher Famulare (= 1×) peers Kai Hu

Countries citing papers authored by Christopher Famulare

Since Specialization

Citations

This map shows the geographic impact of Christopher Famulare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Famulare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Famulare more than expected).

Fields of papers citing papers by Christopher Famulare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Famulare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Famulare. The network helps show where Christopher Famulare may publish in the future.

Co-authorship network of co-authors of Christopher Famulare

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Famulare. A scholar is included among the top collaborators of Christopher Famulare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Famulare. Christopher Famulare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Terry, Alexander R., Andriy Derkach, Kuo‐Kai Chin, et al.. (2025). Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction. Blood Advances. 9(13). 3213–3222.

Derkach, Andriy, Justin C. Wheat, Christopher Famulare, et al.. (2025). AML-1357: Outcomes in Acute Myeloid Leukemia With MECOM Rearrangement (MECOMr-AML) Treated With Hypomethylating Agent Plus Venetoclax. Clinical Lymphoma Myeloma & Leukemia. 25. S503–S503. 1 indexed citations

Burton, H., Andriy Derkach, Christopher Famulare, et al.. (2025). Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs. Cancer. 131(16). e70024–e70024. 1 indexed citations

Chin, Kuo‐Kai, Andriy Derkach, Christopher Famulare, et al.. (2024). HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML. Leukemia & lymphoma. 66(2). 270–278.

Robinson, Troy M., Robert L. Bowman, Ying Liu, et al.. (2023). Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Science Advances. 9(38). eadg0488–eadg0488. 24 indexed citations

Menghrajani, Kamal, Jacob L. Glass, Raajit K. Rampal, et al.. (2023). MPN Transformation Is Characterized By Heterogeneous Shifts in Lineage Character. Blood. 142(Supplement 1). 749–749. 1 indexed citations

Stahl, Maximilian, Kamal Menghrajani, Andriy Derkach, et al.. (2021). Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances. 5(5). 1552–1564. 108 indexed citations

Derkach, Andriy, Alexandra Sherman, Susan J. McCall, et al.. (2021). Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines. Leukemia. 35(12). 3578–3580. 5 indexed citations

Jain, Akriti, Madelyn Burkart, Christopher Famulare, et al.. (2021). Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. Blood. 138(Supplement 1). 32–32. 13 indexed citations

10.

Menghrajani, Kamal, et al.. (2020). Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes. Leukemia Research. 98. 106453–106453. 6 indexed citations

11.

Rampal, Raajit K., Qin Yang, Richard P. Koche, et al.. (2020). Analysis of the Global Methylation Profile of Accelerated and Blast Phase Myeloproliferative Neoplasms and Its Association with Response to Decitabine-Based Therapy. Blood. 136(Supplement 1). 18–20. 2 indexed citations

12.

Santos, Fábio Pires de Souza, Bartlomiej Getta, Lucia Masárová, et al.. (2019). Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 34(3). 799–810. 54 indexed citations

13.

Ball, Brian, Meier Hsu, Sean M. Devlin, et al.. (2019). RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy. Blood. 134(Supplement_1). 18–18. 13 indexed citations

14.

Xiao, Wenbin, Kamal Menghrajani, Christopher Famulare, et al.. (2019). Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia. Blood. 134(Supplement_1). 2718–2718. 1 indexed citations

15.

Goldberg, Aaron D., Chetasi Talati, Pinkal Desai, et al.. (2018). TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia. Blood. 132(Supplement 1). 1433–1433. 35 indexed citations

16.

Talati, Chetasi, Aaron D. Goldberg, Amanda Przespolewski, et al.. (2018). Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy. Blood. 132(Supplement 1). 665–665. 5 indexed citations

17.

Ahr, Katya, Christopher Famulare, Richard P. Koche, et al.. (2018). AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival. Blood. 132(Supplement 1). 1471–1471. 2 indexed citations

18.

Talati, Chetasi, Aaron D. Goldberg, Pinkal Desai, et al.. (2018). Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia. Blood. 132(Supplement 1). 2741–2741. 5 indexed citations

19.

Menghrajani, Kamal, Franck Rapaport, Caroline McNamara, et al.. (2017). SETBP1 and NRAS Mutations Are Frequent Events in Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML) Lacking JAK-STAT Activating Mutations. Blood. 130. 203–203. 1 indexed citations

20.

Vu, Ly, Brian F. Pickering, Yuanming Cheng, et al.. (2017). The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nature Medicine. 23(11). 1369–1376. 932 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact